Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Vimpat (lacosamide) tablets, injection, and oral solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2013

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • Cardiac disorders: Bradycardia
  • Psychiatric disorders: hallucination
  • Skin and subcutaneous tissue disorders: Rash

 

-
-